IDH1 and central nervous system cancer: However, most studies in this analysis did not take into account confounding factors such as IDH1/2 mutational status, and a subgroup analysis of types of gliomas showed that impact of loss of 9p on overall survival was particularly present in the glioblastoma subtype.